Company: INMB
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003354
Chunk: 304

Company: Inmune Bio, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1B
Chunk 304
---
 Company’s
product candidates are still in development and, to date, none of the Company’s product candidates have been approved for sale.

There can
be no assurance that the Company’s research and development will be successfully completed, that adequate protection for the Company’s
intellectual property will be obtained or maintained, that any products developed will obtain necessary government regulatory approval
or that any approved products will be commercially viable. Even if the Company’s product development efforts are successful, it
is uncertain when, if ever, the Company will generate any revenue from any of its products. The Company operates in an environment of
rapid change in technology and substantial competition from other pharmaceutical and biotechnology companies.

The Company
relies and expects to continue to rely on a small number of vendors to manufacture supplies and materials for its use in the clinical
trial programs. These programs could be adversely affected by a significant interruption in these manufacturing services.

Cash and Cash Equivalents

The Company considers all highly liquid instruments
purchased with an original maturity of three months or less to be cash equivalents. The Company holds cash in banks in excess of Federal
Deposit Insurance Corporation insurance limits. However, the Company believes risk of loss is minimal as the cash is held by large, highly-rated
financial institutions. 

F-8

Research and Development Tax Incentive Receivable

The Company, through its wholly-owned subsidiary
in Australia, participates in the Australian research and development tax incentive program, such that a percentage of our qualifying
research and development expenditures are reimbursed by the Australian government, and such incentives are reflected as a reduction of
research and development expense. The Australian research and development tax incentive is recognized when there is reasonable assurance
that the incentive will be received, the relevant expenditure has been incurred and the amount of the consideration can be reliably measured.
At each period end, management estimates the reimbursement available to the Company based on available information at the time.

The Company, through its wholly-owned subsidiary
in the United Kingdom, participates in the research and development program provided by the United Kingdom tax relief program, such that
a percentage of our qualifying research and development expenditures are reimbursed by the United Kingdom government, and such incentives
are reflected as a reduction of research and development expense. The United Kingdom research and development tax incentive is recognized
when there is reasonable assurance that the incentive will be received, the relevant expenditure has been incurred and the amount of the
consideration can be reliably measured. At each period end, management estimates the reimbursement available to the Company